A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats

International Journal of Impotence Research

Volumn 16, Issue 6, 2004, Pages 479-485

  Kalsi, Jasjit S ^a,b   Ralph, David J ^b   Madge, David J ^a   Kell, Phil D ^b   Cellek, Selim ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

BAY41 2272; Diabetes mellitus; Erectile dysfunction; NCX 911; Nitric oxide; PDE5 inhibitors; Sildenafil; Soluble guanylyl cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; GUANYLATE CYCLASE ACTIVATOR; NITRIC OXIDE DONOR; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SILDENAFIL NITRATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOCOCCYGEUS MUSCLE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG POTENCY; ERECTILE DYSFUNCTION; MALE; NITRERGIC NERVE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ADRENERGIC ALPHA-AGONISTS; ANAL CANAL; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; ELECTRIC STIMULATION; MALE; MUSCLE RELAXATION; MUSCLES; NITRERGIC NEURONS; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; SACROCOCCYGEAL REGION;

EID: 6344233551     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901224     Document Type: Article

References (32)

1. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res 2003; 15: 63-71.
2. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-1404.
3. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diahetes: a randomized controlled trial. Sildenafil Diahetes Study Group. JAMA 1999; 281: 421-426.
4. Stuckey BG et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003; 26: 279-284.
5. Cellek S et al. Selective nitrergic neurodegeneration in diabetes mellitus-a nitric oxide-dependent phenomenon. Br J Pharmacol 1999; 128: 1804-1812.
6. Cellek S, Moncada S. Nitrergic neurotransmission in the physiology of penile erection and pathophysiology of erectile dysfunction. In: Toda N, Moncada S, Furchgott R, Higgs EA (eds). Nitric Oxide and the Peripheral Nervous System. Portland Press: London, 2000, pp 61-76.
7. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin diabetic rats. Diabetes 2003; 52: 2353-2362.
8. Cellek S, Rees RW, Kalsi J. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-ieleasing PDE5 inhibitor: novel approaches to erectile dysfunction. Expert Opin Invest Drugs 2002; 11: 1563-1573.
9. Brioni JD et al. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res 2002; 14: 8-14.
10. Gibson A, McFadzean L. Biology of the anococcygeus muscle. Int Rev Cytol 2001; 205: 1-35.
11. Cheah LS, Gwee MC, Nirthanan S. Characterisation of the rat isolated retractor penis muscle as a model for the study of nitrergic transmission. J Pharmacol Toxicol Methods 2002; 47: 79-85.
12. Kasakov L, Cellek S, Moncada S. Characterization of nitrergic neurotransmission during short- and long-term electrical stimulation of the rabbit anococcygeus muscle. Br J Pharmacol 1995; 115: 1149-1154.
13. Way KJ, Reid JJ. Nitric oxide-mediated neurotransmission is attenuated in the anococcygeus muscle from diabetic rats. Diabetologia 1994; 37: 232-237.
14. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001; 53: 417-450.
15. Saenz de Tejada I et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diahetic men with impotence. N Engl J Med 1989; 320: 1025-1030.
16. Pickard RS, King P, Zar MA, Powell PH. Corpus cavernosal relaxation in impotent men. Br J Urol 1994; 74: 485-491.
17. Pickard RS, Powell PH, Zar MA. Nitric oxide and cyclic GMP formation following relaxant nerve stimulation in isolated human corpus cavernosum. Br J Urol 1995; 75: 516-522.
18. Azadzoi KM, Saenz de Tejada I. Diahetes mellitus impairs neurogenic and endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1992; 148: 1587-1591.
19. Rehman J et al. Diminished neurogenic but not pharmacological erections in the 2- to 3-month experimentally diabetic F-344 rat. Am J Physiol 1997; 272: H1960-H1971.
20. Khan MA et al. The effect of Superoxide dismutase on nitric oxide-mediated and electrical field-stimulated diabetic rabbit cavernosal smooth muscle relaxation. Br J Urol Int 2001; 87: 98-103.
21. Vernet D et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995; 136: 5709-5717.
22. Podlasek CA et al. Characterization and localization of nitric oxide synthase isoforms in the BB/WOR diabetic rat. J Urol 2001; 166: 746-755.
23. Akingba AG, Burnett AL. Endothelial nitric oxide synthase protein expression, localization, and activity in the penis of the alloxan-induced diahetic rat. Mol Urol 2001; 5: 189-197.
24. El-Sakka AI et al. Effects of diahetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res 1999; 11: 123-132.
25. Cashen DE, MacIntyre DE, Martin WJ. Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase. Br J Pharmacol 2002; 136: 693-700.
26. Thompson CS et al. The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diahetic rabbit. Eur J Pharmacol 2001; 425; 57-64.
27. Seidler M et al. In vitro effects of a novel class of nitric oxide (NO) donating compounds on isolated human erectile tissue. Eur Urol 2002; 42: 523-528.
28. Riffaud JP et al. Pharmacological profile of sildenafil nitrate (NCX 911) in various models of penile erection. Inflammation Res 2001; 50(Suppl 3): S84.
29. Stasch JP et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410: 212-219.
30. Kalsi JS et al. BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol 2003; 169: 761-766.
31. Becker EM et al. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY41-2272. BMC Pharmacol 2001; 1: 13-25.
32. Bischoff E et al. BAY41-2272: a stimulator of soluble guanylate cyclase induces nitric oxide-dependent penile erection in vivo. Urology 2003; 61: 464-467.